ReviewJournal of human hypertension2002
Angiotensin II as a cardiovascular risk factor.
Review in Journal of human hypertension, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 92 citations in OpenAlex.
- Article
- Rab10 plays a protective role in the development of pathological cardiac hypertrophy.Journal of molecular and cellular cardiology plus · 2025Article
- Role of LMCD1 in the Long-Term Effects of Angiotensin II in Vascular Smooth Muscle Cells.International journal of molecular sciences · 2025Article
- Supplementation with the Postbiotic BPL1™-HT (Heat-InactivatedAntioxidants (Basel, Switzerland) · 2025Article
- Chronic vagus nerve stimulation in patients with heart failure: challenge or failed translation?Frontiers in cardiovascular medicine · 2023Review
- Alterations in Renin-Angiotensin System (RAS) Peptide Levels in Patients with HIV.Metabolites · 2022Article
- Review
- Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2022Article
- Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction.Bioactive materials · 2021Review
- The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19.Acta diabetologica · 2021Review
- Epigenetic Regulation of Autophagy in Cardiovascular Pathobiology.International journal of molecular sciences · 2021Review
- Impact of Dietary Restriction Regimens on Mitochondria, Heart, and Endothelial Function: A Brief Overview.Frontiers in physiology · 2021Review
- Lifestyle-Induced Redox-Sensitive Alterations: Cross-Talk among the RAAS, Antioxidant/Inflammatory Status, and Hypertension.Oxidative medicine and cellular longevity · 2021Article
- Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis.European heart journal · 2020Article
- Angiotensin II Destabilizes Coronary Plaques in Watanabe Heritable Hyperlipidemic Rabbits.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension.American journal of hypertension · 2014Article
- Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.World journal of hypertension · 2012Article
- Plasminogen activator inhibitor-1 deficient mice are protected from angiotensin II-induced fibrosis.Archives of biochemistry and biophysics · 2011Article
- Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.Cardiology research and practice · 2011Article
- Angiotensin II induces afterdepolarizations via reactive oxygen species and calmodulin kinase II signaling.Journal of molecular and cellular cardiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A renin-angiotensin level that is inappropriately high for the systemic blood pressure and the state of sodium balance is now recognized to be one of the modifiable cardiovascular risk factors. Angiotensin acts both as a circulating hormone and as a locally acting paracrine/autocrine/intracrine factor. The adverse effects of angiotensin on the heart include the mechanical results of elevated resistance to the pumping function of the myocardium, as well as the effects of neurohumoral abnormalities on various cardiac structures. In addition, cardiac damage follows acute ischaemic injury or chronic energy starvation due to coronary artery disease, attributable to either mechanical obstruction (atherosclerotic and/or thrombotic) or functional stenosis (vasospasm). Activation of the renin-angiotensin system has several haemodynamic and humoral consequences, all of which may damage the myocardium. These include acute myocardial ischaemia, left-ventricular hypertrophy, arrhythmias, alterations in the coagulation-fibrinolysis equilibrium, increased oxidative stress, and pro-inflammatory activity. A brief review of some of the mechanisms by which activation of the renin-angiotensin system can inflict damage on the heart is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.